Citations

Clear

25 citation(s) found for "Molinaro, Annette M".

MRI Deep Learning for Differentiating Glioblastoma, IDH Wild-type from Central Nervous System Diffuse Large B-cell Lymphoma
Moassefi, Mana , Decker, Paul A. , Conte, Gian Marco , Kosel, Matthew L., Molinaro, Annette M. , Niederschweiberer, Moritz , Nikanpour, Yalda , Ruff, Michael W. , Burns, Terry C. , Farooq, Umar , Derdeyn, C, Jenkins, RB , Lachance, Daniel H , Eckel‐Passow, Jeanette E. , Kosel, Matthew , Niederschweiberer, Moritz A , Derdeyn, Colin P , Habermann, Thomas , Cerhan, James R , Greenlee, Jeremy D W , Howard, Matthew A , Slager, Susan L , Vaubel, Rachael A , Lachance, Daniel , Erickson, Bradley J , Tobin, W Oliver , Eckel-Passow, Jeanette E , Farooq, Umar , Conte, Gian Marco , Burns, Terry C , Moassefi, Mana , Decker, Paul A. , Kosel, Matthew , Molinaro, Annette M. , Derdeyn, Colin P. , Habermann, Thomas M. , Cerhan, James R. , Greenlee, Jeremy D.W. , Howard, Matthew A. , Slager, Susan L. , Vaubel, Rachael A. , Jenkins, Robert B. , Erickson, Bradley J.

Mayo Clinic

Cancer Research Communications | May 4, 2026 | Volume: 6 | Issue: 5 | Pages: 1168-1179

10.1158/2767-9764.crc-25-0710 | PMID 42081255 Get It

Abstract Glioblastoma (GBM), isocitrate dehydrogenase wild-type (IDHwt) and central nervous system diffuse large B-cell lymphoma (CNS-DLBCL) are aggressive brain tumors with overlapping MRI features, yet distinct treatment approaches. Noninvasive tools are needed to aid in differential diagnosis. Deep learning on T1 postcontrast and T2-weighted MRI sequences were used to differentiate GBM and CNS-DLBCL. A three-stage temporal study design was utilized. Model development was performed on 146 patients with CNS-DLBCL and 146 age-matched, sex-matched, and MRI year–matched patients with GBM diagnosed at Mayo Clinic between 1998 and 2019. Models were tested on independent temporal test cohorts. Initial testing included 240 independent GBM diagnosed at Mayo Clinic between 1998 and 2019. The prospective test cohort included 37 patients with CNS-DLBCL and 256 patients with GBM diagnosed at Mayo Clinic after January 1, 2020, and 36 patients with CNS-DLBCL diagnosed at an external institution. Of the patients diagnosed at Mayo Clinic, 47% had MRIs generated from non-Mayo institutions. Two different model approaches were compared: (i) ensemble approach using area under the receiver operating characteristic curve (AUC) and cross-validation for model selection and (ii) loss approach minimizing cross-entropy loss and cross-validation to evaluate prediction performance. The AUCs on the prospective test cohort were 0.84 [95% confidence interval (CI), 0.78–0.90] and 0.83 (95% CI, 0.77–0.88) for the ensemble and loss approaches, respectively. Stability of ensemble prediction improved with the increasing number of models. Stratified AUC analysis demonstrated consistent performance across sex and age. We utilized a robust temporal study design and applied 2 different analytic approaches to develop a classification model. The findings confirm the feasibility of using MRI-based deep learning models to differentiate GBM from CNS-DLBCL. Significance: GBM, IDHwt and CNS-DLBCL are aggressive brain tumors with overlapping MRI features, yet distinct treatment approaches. Noninvasive tools are needed to aid in differential diagnosis. We developed MRI-based deep learning models to differentiate GBM, IDHwt from CNS-DLBCL using a rigorous three-stage temporal design that included prospective validation. The model AUC on a prospective cohort was 0.84.
PATH-82. Multivariate survival risk stratification in GBMs lacking necrosis and microvascular proliferation
Molinaro, Annette M, McCoy, Lucie , Warrier, Gayathri , Al-Adli, Nadeem , Mendez, Joe , Malani, Rachna , Hamel, Elaine, Odell, Jennifer Ledbetter, Reardon, David A. , Decker, Paul, Eckel‐Passow, Jeanette E. , Kosel, Matthew , Kollmeyer, Thomas M. , Kizilbash, Sani H. , Jenkins, Robert B. , Wen, Patrick Y. , Solomon, David, Chang, Susan M. , Colman, Howard , Kollmeyer, Thomas , Kizilbash, Sani H , Warrier, Gayathri , Young, Jacob S. , Hamel, Elaine, Odell, Jennifer Ledbetter, Eldred, Blaine S.C. , Nghiemphu, Phioanh L. , Liau, Linda M. , Ligon, Keith L , Lachance, Daniel Honore , Burns, Terry C. , Ida, Cristiane M. , Vaubel, Rachael A. , Giannini, Caterina , Maqbool, Muhammad Asad , Shafqat, Shameel , Mansouri, Alireza , Cloughesy, Timothy F. , Lai, Albert, Youssef, Gilbert , Wen, Patrick Yung , Groot, John de , Colman, Howard

Mayo Clinic

Neuro-Oncology | November 11, 2025 | Volume: 27 | Issue: Supplement_5 | Pages: v260-v261

10.1093/neuonc/noaf201.1034 Get It

Abstract IDH-wildtype diffuse astrocytic gliomas with lower-grade histological features alongside specific genomic alterations (e.g., TERT promoter mutation, EGFR amplification, gain Chr7/loss Chr10) are presently diagnosed as glioblastoma, IDH-wildtype (GBM) under WHO 2021 criteria. Previous analyses categorized these into “early/evolving” or “surgically undersampled” GBMs. However, it remains unclear whether these tumors share identical clinical and prognostic features with histologic GBM. Data from IDH-wt molecular GBMs across six institutions were aggregated. Astrocytic IDH-wt tumors of any grade that lacked necrosis or microvascular proliferation on initial histopathology yet exhibited molecular alterations consistent with WHO 2021 GBM diagnosis, were included. Recursive partitioning analysis (RPA) was used to categorize patients into risk groups based on overall survival (OS). Among the 264 patients included, the median age was 60 years (IQR: 51-67), with 162 (61%) being male. Additionally, 210 (80%) were diagnosed since 2016, and 216 (82%) received chemoradiation plus adjuvant temozolomide (GBM-SOC). The median follow-up period was 3.9 years (95% CI: 3.4, 4.6). Identified univariate risk factors for worse survival included older age, biopsy-only status, EGFR amplification, absence of initial adjuvant treatment, low post-operative KPS, and tumor histologic grade of 3. RPA divided patients into four distinct survival groups (p<0.0001). The “best” risk group comprised lower grade (<=2) tumors (n=58, median OS (mOS): 40 months (95% CI: 33, NA)). The “second best” group included Grade 3 patients receiving GBM-SOC without steroids during initial RT (n=139, mOS: 25 months (95% CI: 22, 28)). The “second worst” group encompassed Grade 3 patients who were on steroids during initial RT while receiving GBM-SOC (n=38, mOS: 15 months (95% CI: 13, 20)). The “worst” group contained Grade 3 tumors that had not undergone SOC (n=29, mOS: 9 months (95% CI: 4, 26)). These data show that histologic features and treatment are strong indicators of patient outcomes.
Dissecting the biology of gliomagenesis: Evaluating the interaction between IDH tumor mutation and germline variants
Kosel, Matthew , Decker, Paul A. , Kollmeyer, Thomas M. , Shurtz, Anne K., Molinaro, Annette M. , Moassefi, Mana , Wrensch, Margaret , Jenkins, Robert B. , Eckel‐Passow, Jeanette E. , Vaubel, Rachel A, Jenkins, RB , Eckel-Passow, Jeanette E , Kollmeyer, Thomas , Decker, Paul A. , Drucker, Kristen , Molinaro, Annette M. , Conte, Gian Marco , Moassefi, Mana , Erickson, Bradley J. , Wiencke, John K. , Francis, Stephen , Burns, Terry C. , Vaubel, Rachael A. , Lachance, Daniel Honore , Tobin, W. Oliver

Mayo Clinic

Neuro-Oncology Advances | July 8, 2025 | Volume: 7 | Issue: 1 | Pages: No page available

10.1093/noajnl/vdaf147 | PMID 40709013 Get It

Abstract Background The CCDC26 germline variant rs55705857 is causal for development of IDH mutant (IDHmut) adult glioma. However, ~60% of IDHmut patients do not carry the rs55705857 risk allele. We aimed to identify variants associated with developing IDHmut glioma among patients that do not have the rs55705857 risk allele and to further understand development of IDHwt glioma. Methods We used three datasets that included 1216 IDHmut and 1442 IDHwt glioma patients and a case–case design to perform genome-wide association (GWAS) analyses comparing IDHmut versus IDHwt glioma. Analyses were performed overall and stratified by rs55705857 genotype and sex. Multivariable logistic regression and regression trees were used to develop models to predict IDH status using germline variants, age, and contrast enhancement on MRI. Results Three regions were identified comparing IDHmut versus IDHwt: rs55705857 (meta P-value [P] = 1.35 × 10−43), PHLDB1 (rs7125115, P = 3.46 × 10−17), and D2HGDH (rs71430382, P = 2.43 × 10−12). When analyzing only patients that do not have the rs55705857 risk allele, PHLDB1 (rs7125115, P = 1.73 × 10−13) and D2HGDH (rs71430382, P = 8.86 × 10−10) were identified. Among patients who have the rs55705857 risk allele, four variants between ROBO1 and ROBO2 (rs4680975, P = 4.65 × 10−7) increased the likelihood of having an IDHwt tumor. Tumor expression of ROBO1 was associated with rs4680975 genotype in IDHwt patients that have the rs55705857 risk allele (P = 0.034). Multivariable logistic analysis demonstrated that rs55705857, rs71430382 (D2HGDH), and age predicted IDH mutation status. Conclusions To understand the development of adult glioma, we demonstrate that D2HGDH and PHLDB1 should be prioritized for functional studies in IDHmut tumors. The ROBO1 region warrants further investigation in IDHwt tumors.
Predicting therapeutic clinical trial enrollment for adult patients with low- and high-grade glioma using supervised machine learning
Mehari, Mulki , Warrier, Gayathri , Dada, Abraham , Kabir, Aymen , Haskell-Mendoza, Aden , Tripathy, Arushi , Jha, Rohan , Nieblas‐Bedolla, Edwin , Jackson, Joshua , Gonzalez, Ariel T , Reason, Ellery , Flusché, Ann Marie , Reihl, Sheantel , Dalton, Tara , Negussie, Mikias , Gonzales, Cesar Nava, Ambati, Vardhaan , Desjardins, Annick , Krishna, Saritha, Chang, Susan M. , Porter, Alyx B. , Fecci, Peter E. , Hollon, Todd , Chukwueke, Ugonma , Badal, Kimberly , Molinaro, Annette M. , Hervey‐Jumper, Shawn L. , Haskell-Mendoza, Aden P , Reason, Ellery H , Ambati, Vardhaan , Krishna, Saritha , Porter, Alyx , Hollon, Todd , Chukwueke, Ugonma N , Badal, Kimberly , Molinaro, Annette M. , Hervey-Jumper, Shawn L , Reihl, Sheantel J , Fecci, Peter E , Desjardins, Annick , Daniel, Andy G. S.

Mayo Clinic

Science Advances | June 11, 2025 | Volume: 11 | Issue: 23 | Pages: No page available

10.1126/sciadv.adt5708 | PMID 40465719 Get It

Therapeutic clinical trial enrollment does not match glioma incidence across demographics. Traditional statistical methods have identified independent predictors of trial enrollment; however, our understanding of the interactions between these factors remains limited. To test the interactive effects of demographic, socioeconomic, and oncologic variables on trial enrollment, we designed boosted neural networks (BNNs) for all glioma patients ( n = 1042), women ( n = 445, 42.7%), and minorities ( n = 151, 14.5%) and externally validated these models [whole cohort, n = 230; women, n = 89 (38.7%); minority, n = 66 (28.7%)]. For the whole-cohort BNN, the most influential variables on enrollment were oncologic variables, including KPS [total effect (TE), 0.327], chemotherapy (TE, 0.326), tumor location (TE, 0.322), and seizures (TE, 0.239). The women-only BNN exhibited a similar trend. Conversely, for the minority-only BNN, socioeconomic variables [insurance status (TE, 0.213), occupation classification (TE, 0.204), and employment status (TE, 0.150)] were most influential. These results may help prioritize patient-specific initiatives to increase accrual.
Functional germline variants in DNA damage repair pathways are associated with altered survival in adults with glioma treated with temozolomide
Guerra, Geno , Wendt, George A. , McCoy, Lucie , Hansen, Helen M. , Kachuri, Linda , Molinaro, Annette M. , Rice, Terri, Guan, Victoria, Capistrano, Lianne, Hsieh, Allison, Kalsi, Veruna, Sallee, Jaimie, Taylor, Jennie , Clarke, Jennifer , Eckel‐Passow, Jeanette E. , Jenkins, Robert B. , Wrensch, Margaret , Francis, Stephen , Taylor, Jennie W , Jenkins, RB , Francis, Stephen S , Guerra, Geno A , Kachuri, Linda , Molinaro, Annette M. , Hsieh, Allison, Sallee, Jaimie, Almaraz, Eduardo Rodriguez , Wiencke, John K.

Mayo Clinic

Neuro-Oncology | December 24, 2024 | Volume: 27 | Issue: 5 | Pages: 1385-1398

10.1093/neuonc/noae275 | PMID 39745907 Get It

Abstract Background Temozolomide (TMZ) treatment has demonstrated a variable impact on glioma prognosis. This study examines associations of survival with DNA repair gene germline polymorphisms among glioma patients who did and did not have TMZ treatment. Identifying genetic markers which sensitize tumor cells to TMZ could personalize therapy and improve outcomes. Methods We evaluated TMZ-related survival associations of pathogenic germline SNPs and genetically predicted transcript levels within 34 DNA repair genes among 1504 glioma patients from the University of California San Francisco Adult Glioma Study (UCSF AGS) and Mayo Clinic, whose diagnoses spanned pre- and post-TMZ eras within the major known glioma prognostic molecular subtypes. Results Among those who received TMZ, 5 SNPs were associated with overall survival, but not in those who did not receive TMZ. Only rs2308321-G, in MGMT, was associated with decreased survival (hazard ratio = 1.21, P = .019) for all glioma subtypes. Rs73191162-T (near UNG), rs13076508-C (near PARP3), rs7840433-A (near NEIL2), and rs3130618-A (near MSH5) were only associated with survival and TMZ treatment for certain subtypes, suggesting subtype-specific germline chemosensitization. Genetically predicted elevated expression of PNKP, compared to normal brain expression, was associated with markedly poor survival in TMZ-treated patients with isocitrate dehydrogenase (IDH)-mutant and 1p/19q non-codeleted gliomas (P = .015), with a median difference of over 70 months in overall survival times. Similarly, NEIL2 and TDG expressions were associated with altered TMZ-related survival only among certain subtypes. Conclusions Functional germline alterations within DNA repair genes were associated with TMZ sensitivity, measured by overall survival among adults with glioma. These variants should be evaluated in prospective analyses and functional studies.
DISP-05. SUPERVISED MACHINE LEARNING PREDICTION OF THERAPEUTIC CLINICAL TRIAL ENROLLMENT FOR MINORITY PATIENTS AND WOMEN IN NEURO-ONCOLOGY
Mehari, Mulki , Warrier, Gayathri , Dada, Abraham , Kabir, Aymen , Reihl, Sheantel , Jackson, Joshua , González, Ariel, Reason, Ellery H, Dalton, Tara , Negussie, Mikias , Gonzales, Cesar Nava, Chukwueke, Ugonma , Molinaro, Annette M, Porter, Alyx B. , Hervey‐Jumper, Shawn L. , Warrier, Gayathri , Haskell-Mendoza, Aden , Reason, Ellery , Flusché, Ann Marie , Fecci, Peter E.

Mayo Clinic

Neuro-Oncology | November 11, 2024 | Volume: 26 | Issue: Supplement_8 | Pages: viii147-viii147

10.1093/neuonc/noae165.0579 Get It

Abstract BACKGROUND Despite changes in national policy, women and minority patients remain under-accrued in glioma clinical trials. Supervised machine learning may serve as a novel approach to understanding which variables and their complex interplay most influence enrollment for underrepresented patients. We aimed to design and externally validate machine learning models to predict therapeutic clinical trial enrollment for a) all patients, b) women, and c) NIH-designated minority patients with low- and high-grade glioma. METHODS In a 20-year retrospective cohort of 1042 adult patients with low- and high-grade glioma, boosted neural network (BNN) models for the whole, women, and minority cohorts were used to analyze the combined effects of demographic, socioeconomic, and oncologic variables on clinical trial enrollment. These models were validated using an external cohort (n=103). RESULTS In the development cohort (445 [42.7%] women; 151 [14.5%] minorities; median age, 51.5 [interquartile range: 39.4-62.5] years), 350 patients (33.6%) enrolled in a therapeutic clinical trial. The whole cohort BNN (AUC: 0.827, misclassification rate (MR): 0.175), the women cohort BNN (AUC: 0.895, MR: 0.125), and the minority cohort BNN (AUC: 0.983, MR: 0.053) models accurately predicted trial enrollment on external validation. For the whole cohort and women models, several demographic (race, ethnicity, minority status, sex), socioeconomic (insurance, employment status), and oncologic variables (seizure, chemotherapy, KPS, WHO grade, tumor lobe) were equally influential (Main effect (ME): 1.000, Total effect (TE): 1.000) on enrollment. For the minority model, socioeconomic variables including insurance status (ME: 0.089, TE: 0.417) and occupation classification (ME: 0.087, TE: 0.381) drove enrollment. CONCLUSION We designed and externally validated the first machine learning model for predicting therapeutic clinical trial enrollment for patients with diffuse glioma. Model features driving trial enrollment varied for underrepresented patients. These results may help prioritize personalized patient-specific initiatives to address barriers to equitable patient accrual.
EPID-19. INTERACTION BETWEEN GERMLINE AND SOMATIC GENETICS TO ELUCIDATE RISK OF ADULT DIFFUSE GLIOMA
Eckel‐Passow, Jeanette E. , Kosel, Matthew , Decker, Paul A. , Kollmeyer, Thomas M. , Molinaro, Annette M. , Wrensch, Margaret , Jenkins, Robert B. , Kollmeyer, Thomas , Decker, Paul A. , Drucker, Kristen , Molinaro, Annette M. , Francis, Stephen , Wiencke, John K. , Lachance, Daniel Honore , Tobin, W. Oliver

Mayo Clinic

Neuro-Oncology | November 11, 2024 | Volume: 26 | Issue: Supplement_8 | Pages: viii142-viii142

10.1093/neuonc/noae165.0555 Get It

Abstract Acquired tumor alterations are part of the WHO diagnosis of glioma. However, germline predisposition to these alterations is unknown. GWAS in European and Asian populations identified germline variants in 30 regions, many in or near genes that also acquire alterations, suggesting that interactions between inherited and acquired genetics are involved in glioma development. To evaluate such interactions, we used 3686 glioma cases and 1889 controls. A case-control design and multinomial logistic regression were used to identify germline variants associated with development of TERT-promoter mutant gliomas, generating two interesting observations. First, TERT germline variants were associated with predisposition to IDHwt glioma that have a TERT promoter mutation, but not with IDH-mutant codeleted gliomas that have a TERT promoter mutation. Second, two novel regions were observed in this more homogeneous subgroup of TERT mutated tumors: variants in TXNDC11 (OR=2.66, p=5.7x10-8) and RUVBL2 (OR=3.1, p=5.8x10-8). High tumor expression of TXNDC11 is associated with poor prognosis in glioma and RUVBL2 interacts with TERT to affect telomerase activity. Similar analyses are being performed on additional clinically relevant acquired alterations. In parallel, case-case GWAS analyses were performed to evaluate germline variants associated with other tumor alterations. Comparing IDH-mutant versus IDHwt stratified by rs55705857 genotype, the most significant variants were PHLDB1 (p=1.2x10-13) and D2HGDH (p=2.1x10-10), highlighting the importance of these two variants independent of CCDC26 for the development of IDH-mutant glioma. As a parallel approach, we utilized recursive partitioning and regression trees (rpart) to classify IDH mutation status using the 30 known variants. The top four branches of the regression tree included CCDC26, D2HGDH, PHLDB1, and MAML2, as well as two Asian variants (RAB27A, CYP4F12). This highlights the importance of utilizing variants discovered in non-European populations in analyses. Overall, understanding these interactions are necessary to develop therapeutics, stratify clinical trials, and to develop relevant tumor models.
Enhancing neuro-oncology care through equity-driven applications of artificial intelligence
Mehari, Mulki , Sibih, Youssef , Dada, Abraham , Chang, Susan M. , Wen, Patrick Y. , Molinaro, Annette M. , Chukwueke, Ugonma , Budhu, Joshua , Jackson, Sadhana , Porter, Alyx B. , Hervey‐Jumper, Shawn L. , Budhu, Joshua A , Porter, Alyx , Hervey-Jumper, Shawn L , Jackson, Sadhana , Wen, Patrick Yung , Molinaro, Annette M. , McFaline-Figueroa, J Ricardo

Mayo Clinic

Neuro-Oncology | July 25, 2024 | Volume: 26 | Issue: 11 | Pages: 1951-1963

10.1093/neuonc/noae127 | PMID 39159285 Get It

Abstract The disease course and clinical outcome for brain tumor patients depend not only on the molecular and histological features of the tumor but also on the patient’s demographics and social determinants of health. While current investigations in neuro-oncology have broadly utilized artificial intelligence (AI) to enrich tumor diagnosis and more accurately predict treatment response, postoperative complications, and survival, equity-driven applications of AI have been limited. However, AI applications to advance health equity in the broader medical field have the potential to serve as practical blueprints to address known disparities in neuro-oncologic care. In this consensus review, we will describe current applications of AI in neuro-oncology, postulate viable AI solutions for the most pressing inequities in neuro-oncology based on broader literature, propose a framework for the effective integration of equity into AI-based neuro-oncology research, and close with the limitations of AI.
RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults
Wen, Patrick Y. , Bent, Martin J. van den , Youssef, Gilbert , Cloughesy, Timothy F. , Ellingson, Benjamin M. , Barboriak, Daniel P. , Groot, John de , Huang, Raymond Y. , Lassman, Andrew B. , Molinaro, Annette M. , Rahman, Rifaquat , Shankar, Lalitha , Macdonald, David R., Reardon, David A. , Vogelbaum, Michael A. , Chang, Susan M. , van den Bent, Martin J , Weller, Michael , Barboriak, Daniel P , de Groot, John , Huang, Raymond , Lassman, Andrew B , Mehta, Minesh P , Molinaro, Annette M. , Preusser, Matthias , Rahman, Rifaquat , Stupp, Roger , Villanueva-Meyer, Javier E. , Wick, Wolfgang , Reardon, David A , Vogelbaum, Michael A , Ellingson, Benjamin M , Cloughesy, Timothy F , Wen, Patrick Yung , Galanis, Evanthia , Gilbert, Mark R. , Mehta, Minesh P. , Preusser, Matthias , Stupp, Roger , Wick, Wolfgang

Mayo Clinic

Journal of Clinical Oncology | September 29, 2023 | Volume: 41 | Issue: 33 | Pages: 5187-5199

10.1200/jco.23.01059 | PMID 37774317 Get It

PURPOSE The Response Assessment in Neuro-Oncology (RANO) criteria for high-grade gliomas (RANO-HGG) and low-grade gliomas (RANO-LGG) were developed to improve reliability of response assessment in glioma trials. Over time, some limitations of these criteria were identified, and challenges emerged regarding integrating features of the modified RANO (mRANO) or the immunotherapy RANO (iRANO) criteria. METHODS Informed by data from studies evaluating the different criteria, updates to the RANO criteria are proposed (RANO 2.0). RESULTS We recommend a standard set of criteria for both high- and low-grade gliomas, to be used for all trials regardless of the treatment modalities being evaluated. In the newly diagnosed setting, the postradiotherapy magnetic resonance imaging (MRI), rather than the postsurgical MRI, will be used as the baseline for comparison with subsequent scans. Since the incidence of pseudoprogression is high in the 12 weeks after radiotherapy, continuation of treatment and confirmation of progression during this period with a repeat MRI, or histopathologic evidence of unequivocal recurrent tumor, are required to define tumor progression. However, confirmation scans are not mandatory after this period nor for the evaluation of treatment for recurrent tumors. For treatments with a high likelihood of pseudoprogression, mandatory confirmation of progression with a repeat MRI is highly recommended. The primary measurement remains the maximum cross-sectional area of tumor (two-dimensional) but volumetric measurements are an option. For IDH wild-type glioblastoma, the nonenhancing disease will no longer be evaluated except when assessing response to antiangiogenic agents. In IDH-mutated tumors with a significant nonenhancing component, clinical trials may require evaluating both the enhancing and nonenhancing tumor components for response assessment. CONCLUSION The revised RANO 2.0 criteria refine response assessment in gliomas.
OS09.4.A RANO 2.0: UPDATE TO THE RESPONSE ASSESSMENT IN NEURO-ONCOLOGY (RANO) CRITERIA FOR HIGH- AND LOW-GRADE GLIOMAS IN ADULTS
Wen, Patrick Y. , Youssef, George , Barboriak, Daniel P. , DeGroot, John, Lassman, Andrew B. , Molinaro, Annette M. , Rahman, Rifaquat , Shankar, Lalitha , Sul, Joohee, Villanueva‐Meyer, Javier , Macdonald, David , Reardon, David A. , Vogelbaum, Michael A. , Chang, Susan M. , Barboriak, Daniel P , Wen, Patrick Yung , Bent, Martin J. van den , Youssef, G, Cloughesy, Timothy F. , Ellingson, Benjamin M. , Weller, Michael , Galanis, Evanthia , Gilbert, Mark R. , Huang, Raymond Y. , Mehta, Minesh P. , Molinaro, Annette M. , Preusser, Matthias , Stupp, Roger , Villanueva-Meyer, Javier E. , Wick, Wolfgang

Mayo Clinic

Neuro-Oncology | September 8, 2023 | Volume: 25 | Issue: Supplement_2 | Pages: ii21-ii21

10.1093/neuonc/noad137.061 Get It

Abstract BACKGROUND The Response Assessment in Neuro-Oncology (RANO) criteria for high-grade gliomas (RANO-HGG) and low-grade gliomas (RANO-LGG) were developed to improve reliability of response assessment in glioma trials. Over time some limitations of these criteria were identified, and uncertainty emerged regarding integrating features of the modified RANO (mRANO) or the immunotherapy RANO (iRANO) criteria. MATERIAL AND METHODS Informed by data from a cohort of glioblastoma patients and other evaluations of RANO criteria that allowed evaluation of features of the different criteria, the RANO working group developed updates to the RANO criteria (RANO 2.0). RESULTS Based on the 2021 WHO classification of gliomas, we recommend a standard set of criteria for both high and low-grade gliomas, to be used for all trials regardless of the treatment modalities being evaluated. In the newly diagnosed setting, the post-radiotherapy MRI, rather than the post-surgical MRI, will be used as the baseline for future comparison. Since the incidence of pseudoprogression is high in the 12 weeks following radiotherapy, continuation of treatment and confirmation of progression during this period with a repeat MRI, or histopathologic evidence of unequivocal recurrent tumor, is required to define tumor progression. However, confirmation scans are not mandatory after this period nor for recurrent tumors. For treatments with a high likelihood of pseudoprogression, mandatory confirmation of progression with a repeat MRI is highly recommended. The primary measurement remains the maximum cross-sectional area of tumor (2-dimensional) but volumetric measurements are an option. For IDH-wildtype glioblastoma, the non-enhancing disease will no longer be evaluated. In IDH-mutated tumors with a significant non-enhancing component, clinical trials may require evaluating both the enhancing and non-enhancing tumor components for response assessment. CONCLUSION These criteria represent a work in progress that will hopefully improve the assessment of response in glioma trials. Future updates will incorporate novel developments, advanced imaging techniques, and endpoints as they become validated.